# Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

> **NCT02707328** · PHASE1 · TERMINATED · sponsor: **The Cooper Health System** · enrollment: 30 (estimated)

## Conditions studied

- Pancreas Cancer
- Pancreatic Cancer
- Adenocarcinoma of the Pancreas
- Pancreas Adenocarcinoma
- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** nab-paclitaxel
- **RADIATION:** CyberKnife

## Key facts

- **NCT ID:** NCT02707328
- **Lead sponsor:** The Cooper Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01
- **Primary completion:** 2017-11-10
- **Final completion:** 2017-11-10
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Closed after being on administrative hold
- **Last updated:** 2019-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02707328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02707328, "Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02707328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*